"The lives of millions of the world's poorest citizens critically depend on access to affordable medicines. Unfortunately, today most of the world's population does not receive the essential medicines they need. Priti and Tahir are indeed two of our most valued leaders working on this issue. I-MAK's innovative approach to addressing this crisis represents no less than a wave of hope for patients across the globe."

Dr.Jim Yong Kim, MD PhD, former Director of HIV/AIDS for the World Health Organisation, Co-Founder Partners in Health, President of Dartmouth University

Priti and Tahir are exceptional social entrepreneurs who are tackling a truly global issue. They have designed I-MAK to join multiple stakeholders in ensuring that life-saving pharmaceuticals are affordable to all those around the world who need them. We are proud to support their work.

Cheryl Dorsey, President, Echoing Green

Priti and Tahir are both stellar and unique individuals whose vision has the potential to bring change. It is not only an honor and privilege to know them, but the work that they have done together and individually is an inspiration. Few people in this world lead by example and practice what they preach--Tahir and Priti are the visionary leaders of tomorrow carrying with them a tremendous torch of passion and spirit to advocate for fair and accessible healthcare and treatment for people living with HIV/AIDS.

Shalini Eddens, community advocate for women living with HIV for over 10 years
Director of Training and Education
Women Organized to Respond To Life Threatening Diseases (WORLD)
Oakland, California

"Priti and Tahir's work, vision, energy and zeal coupled with a keen intellect are impacting upon the availability of essential medicines for the poor in emerging nations. I find them to be very intelligent, fair and balanced in their considerations. They are, at the same time, tenacious advocates for the best interests of society…Priti and Tahir are making a very significant impact on the development of a global landscape of IP, contributing to a society in which people no longer need die because of invalid patents covering essential medicines.

On a personal note, Priti and Tahir are absolutely sterling individuals with the highest possible integrity. They represent everything that I want my children to grow up to be... "

Professor Joseph Fortunak, Howard University, Department of Chemistry and Pharmaceutical Sciences, former head of Abbott Laboratories Manufacturing and Process Division, and a scientist in the pharmaceutical industry for over 21 years

“They have applied their knowledge in the formation of I-MAK and this organization can be the epicenter for the humanitarian and social issues arising out of the international misuse of intellectual property, particularly in the area of healthcare and medicine. Their work as bright and intelligent lawyers will certainly provide an extra force in the ongoing battle for access to vital and life-saving medicines at affordable prices not only in the 3rd world but everywhere.”

Dr YK Hamied, Chairman and Managing Director, Cipla Ltd, Mumbai

“Priti Radhakrishnan and Tahir Amin are extraordinarily talented young lawyers who have dedicated themselves to making life better for the world’s less fortunate. Through I-MAK they pursue progressive challenges, often against well-funded and powerful opposition, going where others may be reluctant to tread. They deserve our strong support.”

Professor Fred Abbott
Edward Ball Eminent Scholar
Florida State University
College of Law

"We are absolutely thrilled to have Priti as an Asia Society Asia 21 Fellow for the class of 2009-2010, joining a select group of Asia’s and America’s most dynamic next generation leaders. Priti's drive, passion, and commitment to human rights and values-based leadership will be a tremendous asset to the Asia 21 program, and help her work with the other fellows to collectively address some of the Asia-Pacific region’s greatest challenges."

Jamie Metzl, Executive Vice President, Asia Society

I am a researcher in public health specialized in pharmaceutical policy analysis. I think that I-MAK is an important initiative in the field of IP and access to medicines. As a non-governmental organization with highly skilled and motivated staff it has the possibility to assist a wide range of entities in their endeavor to provide assess to affordable and high quality medicines. I had the opportunity to work with I-MAK during our policy workshop in Mexico in July 2008 and they gave an excellent presentation on IP issues related to access to medicines comparing different countries. I am looking forward to continue my collaboration with I-MAK in the future.

Veronika Wirtz, PhD, MSc, National Institute of Public Health, Mexico

I-MAK is a critically important organization that helps fight to ensure that nascent intellectual property protections for pharmaceutical products being instituted in low- and middle-income countries do not damage the public health. They also help prevent inappropriate patents from restricting access to life-saving therapies across the globe. Priti and Tahir are committed professionals who understand the big picture issues related to intellectual property and public health, but also know how to get important policies implemented on the ground.

Aaron S. Kesselheim, M.D., J.D., M.P.H., Instructor in Medicine at Harvard Medical School and Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, AHRQ Post-Doctoral Fellow at the Department of Health Policy and Management, Harvard School of Public Health.

Priti and Tahir of I-MAK display a relentless commitment to social justice in their quest for access to affordable, effective medicines for all. I was a first-hand witness to this commitment while working with them and continue to be amazed by their continuing dedication and passion for this urgent global health issue.

Dr. Padma Shetty, USAID

"In the information age, a peaceful civil society cannot survive without freedom of and access to knowledge. We must have patriots willing to sacrifice personal gain to battle the forces scheming to co-opt human thought into the hands of a few, else we run the risk of being forever beholden to the privileged information brokers. Priti and Tahir are two such patriots and we owe them a debt of gratitude for the commitment they have made to protect our right to life, liberty and the pursuit of happiness without begging a clan of knowledge monopolists for permission
to do so."

Daniel Ravicher, Executive Director, Public Patent Foundation

"Over the last two years, I-MAK's patent analysis helped to frame my understanding of this critically important area of health policy. Priti and Tahir are thorough and elegant in their approach to the problems they tackle -- and their work product is first rate. What's more, they are evidence-based advocates, and they have already achieved important breakthroughs in systemic reform of the intellectual property system. I look forward to working with both of them in the years to come."

Rahul Rajkumar, MD, JD is a physician at Brigham and Women's Hospital in Boston, MA.

When Priti Radhakrishnan shared I-MAK’s vision and early accomplishments at the 2008 PopTech conference, the message she sent was resounding: those blocking access to key medicines had better get out of the way. I-MAK’s impact is far-reaching. When I-MAK challenged HIV-drug patents, they helped make treatment affordable for millions who would die without it. Priti’s grit is born of seeing too many people – both strangers and friends – die needlessly, and has given her the courage to take bold and highly effective action. A member of the inaugural class of PopTech Social Innovation Fellows, Priti set the perfect example: a visionary change agent, putting all her skills and commitment to work on solving a key global challenge. Her leadership has positioned I-MAK to spur medical innovation and fight for access to crucial treatments worldwide.

Andrew Zolli, Executive Director, The PopTech Institute

The relationship between access to medicines, intellectual property and policy is complex, requiring special expertise. I-MAK provides just such needed expertise and experience. I-MAK meets a truly unmet need at the intersection of policy and technology. Priti and Tahir are experts capable of dealing with science, technology and the law but also, even more importantly, are capable of translating this complexity into terms that policy makers and non-scientists can understand. I-MAK should be congratulated and encouraged to continue their efforts on behalf of those who are demanding more equitable access to medicines.

Warren Kaplan, Assistant Professor, International Health (DIH)
Center for International Health & Development, Boston University School of Public Health

“I-MAK has quickly grown into an organization that is playing a dynamic role in ensuring poor people’s access to medicines. Oxfam looks to I-MAK to provide precise, reliable and cutting-edge advice on how intellectual property rules affect access to medicines today. Tahir's in-depth research, on behalf of Oxfam, on the emerging use of voluntary licensing by pharmaceutical companies played an important role in Oxfam’s assessment of pharmaceutical companies. I-MAK is also harnessing both law and science to expand the use of patent oppositions. Patent oppositions are essential to preventing pharmaceutical companies from abusing the patent system to prevent low-cost generic competition - which plays a critical role in ensuring poor people’s access to affordable medicines.”

Rohit Malpani, Oxfam International Access to Medicines campaign lead

"This is a very important victory for access to medicines. Bravo to Tahir, Priti, and IMAK. Because of this decision, Lopinavir/ritonavir will no longer be blocked from manufacture and consumption and/or export in India. Given growing evidence that the India Patent Office is not being uniformly rigorous in applying its strict patentability standards under Section 3(d) and thus is incorrectly allowing occasional patents on new uses, chemical variations, new formulations, and new combinations (even in the absence of evidence of increased efficacy), it is even more important that there be resources devoted to expert opposition procedures in India."

Professor Brook Baker, Northeastern University School of Law